Table 4.
Patient characteristics for T-cell correlate cohort
| Patient characteristics | Initial vaccination (n = 17) n (%) | Booster vaccination (n = 34) n (%) | |
|---|---|---|---|
| Gender | |||
| Female | 5 (29) | 11 (32) | |
| Male | 12 (71) | 23 (68) | |
| Race | |||
| White | 14 (82) | 31 (91) | |
| Asian | 1 (6) | 0 | |
| American Indian/Alaska native | 0 | 0 | |
| Black | 0 | 1 (3) | |
| Unknown/not reported | 2 (12) | 2 (6) | |
| Age (y) | 63 | 68 | |
| Median | 31-88 | 39-82 | |
| Range | |||
| Y since diagnosis | |||
| Median | 5 | 7 | |
| Range | 2-14 | 1-27 | |
| Vaccine | Initial | Booster | |
| BNT162b2 | 11 | 21 | 25 |
| mRNA-1273 | 5 | 10 | 8 |
| Ad26.COV2.S | 1 | 3 | 1 |
| Absolute lymphocyte count | |||
| Median | 2.18 × 103/μL | 3.09 × 103/μL | |
| Range | 0.78 × 103/μL -97.2 × 103/μL | 0.88 × 103/μL -100.9 × 103/μL | |
| Type of CLL directed therapy | |||
| None | 10 (59) | 15 (44) | |
| BTK inhibitor | 6 (35) | 8 (23) | |
| Venetoclax | 0 | 2 (6) | |
| Venetoclax + CD20 Mab | 0 | 3 (9) | |
| BTK inhibitor + CD20 Mab | 0 | 2 (6) | |
| BTK inhibitor + venetoclax | 1 (6%) | 2 (6) | |
| BTK inhibitor + venetoclax + CD20 Mab | 0 | 2 (6) | |
| Other | 0 | 0 | |
| Months from CD20 Mab exposure | |||
| On treatment - 6 mo | 3 (18) | 5 (15) | |
| 7 to 12 mo | 1 (6) | 2 (6) | |
| >12 mo | 5 (29) | 7 (20) | |
| No exposure | 8 (47) | 20 (59) | |